Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in conjunction with their partner Biogen's ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...